Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01937715 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01937715 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT01937715, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI. The randomized, two-arm Phase 2 portion will compare the efficacy and safety of PF-05212384 plus FOLFIRI to that of bevacizumab plus FOLFIRI. The study population will consist of patients with mCRC previously treated with an oxaliplatin-based regimen in the first line setting or who have progressed within 6 months of the end of an adjuvant oxaliplatin-based regimen.
Interventions
- BIOLOGICAL Bevacizumab
- DRUG FOLFIRI
- DRUG FOLFIRI regimen
- DRUG PF-05212384
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01937715
The ClinicalTrials.gov registry entry for NCT01937715 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01937715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01937715 about?
NCT01937715 is a clinical study titled "A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer". This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI. The randomized, two-arm Phase 2 portion will compare the efficacy and safety of PF-05212384 plus FOLFIRI to that of...
What is the current status of trial NCT01937715?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-02. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01937715?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), FOLFIRI (DRUG), FOLFIRI regimen (DRUG), PF-05212384 (DRUG).
Who is sponsoring clinical trial NCT01937715?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.